Medivir

Medivir Total Assets

The Total Assets of Medivir (MVIR.ST) as of Nov 7, 2026 is 306.40 M SEK. In the previous year, Total Assets was 172.59 M SEK — a change of 77.53% (higher).

Total Assets

306.40 MSEK

YoY

77.53%

Last updated:

Total Assets of Medivir is 2025 306.40 M SEK. Total Assets of Medivir was 2024 172.59 M SEK. It decreases by 77.53% higher compared to the previous year.

The Medivir Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
419.35 M SEK
Jan 1, 2019
293.46 M SEK
Jan 1, 2020
191.46 M SEK
Jan 1, 2021
335.83 M SEK
Jan 1, 2022
234.20 M SEK
Jan 1, 2023
287.91 M SEK
Jan 1, 2024
172.59 M SEK
Jan 1, 2025
306.40 M SEK
The Medivir Total Assets history
YEARTotal AssetsYoY
306.40 MSEK+77.53%
172.59 MSEK-40.05%
287.91 MSEK+22.94%
234.20 MSEK-30.26%
335.83 MSEK+75.40%
191.46 MSEK-34.76%
293.46 MSEK-30.02%
419.35 MSEK-31.94%
616.17 MSEK-67.93%
1.92 BSEK+18.89%
1.62 BSEK-25.99%
2.18 BSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medivir Stock analysis

What does Medivir do? Medivir AB generates revenue by developing pharmaceutical products, specifically focusing on protease inhibitor design and nucleoside and nucleotide science to create therapies for cancers with unmet medical need. The company operates from its headquarters in Huddinge, Stockholm, and relies on a specialized team of nine full-time employees to drive its research and development efforts. The firm's financial model is supported by its clinical pipeline, which includes remetinostat, a topical histone deacetylase inhibitor currently in phase II clinical studies for cutaneous T-cell lymphoma. Additionally, the company is advancing birinapant in combination with Keytruda for solid tumors in phase I studies, MIV-818 for liver cancer in phase I trials, and MIV-711 for osteoarthritis in an IIa extension study. Beyond these specific assets, Medivir AB sustains its operations through additional research projects conducted in cooperation with other institutions. This collaborative approach complements its internal development programs and contributes to the overall value of its proprietary science and therapeutic candidates. Medivir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medivir stock

Total Assets of Medivir is 306.40 M SEK in 2025.

Total Assets of Medivir changed from 172.59 M SEK to 306.40 M SEK, representing a 77.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Medivir since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Medivir historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medivir

All Key Metrics — Medivir